Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development

Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests. Under the terms of the agreement, Pillar Biosciences will lead the development of a series of diagnostic tests that will be run on the Illumina MiSeq™Dx instrument.

Pillar Biosciences has developed Stem Loop Inhibition Mediated Amplification (SLIMamp®), an innovative technology to maximize the efficiency and performance of targeted NGS panels for the clinical user.

Gang Song, Ph.D., CEO of Pillar Biosciences, stated: “The combination of two state-of the-art NGS technologies, SLIMamp and MiSeqDx, will enable affordable precision medicine and make NGS accessible to clinical laboratories.”

The SLIMamp technology is optimized for highly multiplexed reactions from a single tube with as little as 2.5 ng of DNA, supporting sequencing from FFPE and biofluids. Specifically designed to enable automation, it offers a unique technology that can leverage the power of the MiSeqDx to provide superior uniformity and specificity. SLIMamp based NGS panels provide highly sensitive variant detection in regions of interest including GC-rich regions and low quality samples. Pillar intends to submit multiple NGS assays to the FDA starting in 2018.


Press Contact
William Wright
Director of Sales

About Pillar Biosciences Research Panels

Research-use-only (RUO) panels sold by Pillar (including the ONCO/Reveal Solid Tumor Panel) are neither intended for use in clinical investigations or diagnosis, nor are they intended for validation as laboratory developed tests. Pillar Biosciences does not assist in performing validation or verification of test performance for clinical diagnostic use.

About Pillar Biosciences

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Today, our SLIMamp®- and PiVAT®-based products help high-throughput laboratories boost their research productivity. Regulatory approval for clinical panels is pending.

Don’t Stop Here

More To Explore

This small academic lab ramped up in-house NGS testing despite limited resources, and you can too

“There has been sort of this push to make genomics a send-out endeavor…and we are pushing back.” Dr. Cynthia Schandl is the director of a …

Read More →

Pillar Biosciences Closes $29.7 Million in Series C Financing

Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, …

Read More →

New 47-gene solid tumor panel from Pillar Biosciences now available for research use

Pillar Biosciences, the productivity-focused genomics company, today announced that the Pillar® ONCO/Reveal™ Solid Tumor Panel, a 47-gene enrichment assay is now available for research use. …

Read More →

Pillar NGS panels go global with increased platform versatility

Pillar Biosciences, an NGS diagnostics company based in Boston, MA, announced today that Pillar® ONCO/Reveal™ NGS panels are now compatible with Illumina®, Ion Torrent™, and …

Read More →

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ — Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today that the Columbia Solid Tumor Panel, …

Read More →

Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

SAN FRANCISCO, CA, Jan. 10, 2019 /PRNEWSWIRE/ – Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA and Shanghai, China, is forming …

Read More →
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top